Literature DB >> 21183698

Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib.

Wendy Deenik, Bronno van der Holt, Jeroen J W M Janssen, Isabel W T Chu, Peter J M Valk, Gert J Ossenkoppele, Ilse P van der Heiden, Pieter Sonneveld, Ron H N van Schaik, Jan J Cornelissen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21183698     DOI： 10.1182/blood-2010-07-296954

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  22 in total

1.  ABCB1 polymorphisms correlate with susceptibility to adult acute leukemia and response to high-dose methotrexate.

Authors:  Chuan-Xiang Ma; Yong-Hong Sun; Hai-Ying Wang
Journal:  Tumour Biol       Date:  2015-04-29

2.  ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure.

Authors:  Justine E Marum; David T Yeung; Leanne Purins; John Reynolds; Wendy T Parker; Doris Stangl; Paul P S Wang; David J Price; Jonathan Tuke; Andreas W Schreiber; Hamish S Scott; Timothy P Hughes; Susan Branford
Journal:  Blood Adv       Date:  2017-07-31

Review 3.  Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia.

Authors:  Aritro Nath; Jacqueline Wang; R Stephanie Huang
Journal:  Mol Diagn Ther       Date:  2017-12       Impact factor: 4.074

Review 4.  Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.

Authors:  Stefan Wolking; Elke Schaeffeler; Holger Lerche; Matthias Schwab; Anne T Nies
Journal:  Clin Pharmacokinet       Date:  2015-07       Impact factor: 6.447

Review 5.  Modeling normal and malignant human hematopoiesis in vivo through newborn NSG xenotransplantation.

Authors:  Fumihiko Ishikawa
Journal:  Int J Hematol       Date:  2013-11-21       Impact factor: 2.490

6.  MDR1 polymorphisms have an impact on the prognosis of Chinese diffuse large B cell lymphoma patients.

Authors:  Ying Ni; Guangli Yin; Zhengrui Xiao; Lei Fan; Li Wang; Yujie Wu; Hanxin Wu; Sixuan Qian; Wei Xu; Jianyong Li; Kourong Miao; Hairong Qiu
Journal:  Tumour Biol       Date:  2015-08-19

7.  ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis.

Authors:  Q Zheng; H Wu; Q Yu; D H Dennis Kim; J H Lipton; S Angelini; S Soverini; D Vivona; N Takahashi; J Cao
Journal:  Pharmacogenomics J       Date:  2014-09-23       Impact factor: 3.550

Review 8.  Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.

Authors:  Mohamed A M Ali
Journal:  Mol Diagn Ther       Date:  2016-08       Impact factor: 4.074

9.  ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate.

Authors:  Mohamed A M Ali; Walaa Ali Elsalakawy
Journal:  Med Oncol       Date:  2014-10-11       Impact factor: 3.064

Review 10.  Predicting the response of CML patients to tyrosine kinase inhibitor therapy.

Authors:  Deborah L White; Timothy P Hughes
Journal:  Curr Hematol Malig Rep       Date:  2011-06       Impact factor: 3.952
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.